Literature DB >> 677862

Pharmacology of cefaclor in normal volunteers and patients with renal failure.

J Santoro, B N Agarwal, R Martinelli, N Wenger, M E Levison.   

Abstract

After a 500-mg dose of cefaclor, the mean peak plasma level was 12.4 mug/ml and after a 250-mg dose it was 5 mug/ml in normal volunteers. Food intake significantly reduced absorption. Probenecid prolonged plasma levels. Mean plasma half-life in normal volunteers was 0.8 h. Only about 50% of the dose was excreted in the urine within 4 h in normal volunteers. Plasma half-life in patients with renal insufficiency was only about 3 h, which suggests that cefaclor may be eliminated by nonrenal mechanisms in humans. Urinary levels of cefaclor were adequate to inhibit susceptible pathogens even in patients with moderately severe renal failure. Plasma half-life during hemodialysis was 2.1 h and rose to 2.8 h after dialysis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 677862      PMCID: PMC352368          DOI: 10.1128/AAC.13.6.951

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In vitro activity of cefaclor, a new orally administered cephalosporin antibiotic.

Authors:  J Santoro; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

2.  Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals.

Authors:  H R Sullivan; S L Due; D L Kau; J F Quay; W Miller
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

3.  Comparative pharmacology of cefaclor and cephalexin.

Authors:  O M Korzeniowski; W M Scheld; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

4.  In vitro susceptibility studies with cefaclor and cephalexin.

Authors:  W M Scheld; O M Korzeniowski; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

5.  Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.

Authors:  N J Bill; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

6.  Pharmacology of cefazolin in patients with normal and abnormal renal function.

Authors:  M E Levison; S P Levison; K Ries; D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

7.  Cephalexin therapy as related to renal function.

Authors:  S A Kabins; B Kelner; E Walton; E Goldstein
Journal:  Am J Med Sci       Date:  1970-02       Impact factor: 2.378

8.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.

Authors:  W M Kirby; J B De Maine; W S Serrill
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

9.  Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine.

Authors:  M S Silver; G W Counts; D Zeleznik; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

10.  In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria.

Authors:  S Shadomy; G Wagner; M Carver
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

View more
  11 in total

1.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Cefaclor: summary of clinical experience.

Authors:  R B Kammer; L J Short
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Penetration of cefaclor into bronchial mucosa.

Authors:  G E Marlin; A J Nicholls; G R Funnell; R Bradbury
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

5.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

8.  [In vitro activity of cefaclor (author's transl)].

Authors:  H Knothe
Journal:  Infection       Date:  1979       Impact factor: 3.553

9.  Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.

Authors:  M J Nieto; J M Lanao; A Dominguez-Gil; J M Tabernero; J F Macias
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  [Investigations on the excretion of cefaclor in human bile (author's transl)].

Authors:  O Müller; U Rückert; K Fabricius
Journal:  Infection       Date:  1979       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.